However, a recent multicenter, randomized, double-blind, placebo-controlled trial (NCT 03042143) has found that patients with moderate to severe COVID-19-related ARDS do not benefit from ORBCEL-C (CD362-enriched umbilical cord-derived MSCs), although the application of these MSC cells is considered safe [336]. For further information about the properties and functions of MSCs in ARDS, consider consulting the reviews by Fernandez-Francos et al. [337] and Qin and Zhao [325]. This evidence concerns the gene SDC2 and acute respiratory distress syndrome.